This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellone, G. Articles by Rodeck, U. Search for Related Content PubMed PubMed Citation Articles by Bellone, G. Articles by Rodeck, U.

Aberrant Activation of c-kit Protects Colon Carcinoma Cells against Apoptosis and Enhances Their Invasive Potential¹

Department of Clinical Physiopathology University of Torino, 10126 Torino, Italy [G. B., A. C., N. S., O. B., D. T., C. S., T. M., C. G., M. C., G. E.], and Department of Dermatology and Cutaneous Biology and Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [U. R.]

Multiple genetic aberrations contribute to the development of biologically aggressive, clinically malignant colorectal carcinomas (CRCs). Some of these have been linked to inappropriate signaling through the tyrosine kinase moieties of growth factor receptors. We have described previously (G. Bellone et al., J. Cell. Physiol., 172: 1–11, 1997) that human CRCs overexpress both the receptor tyrosine kinase c-kit and its ligand, stem cell factor (SCF), relative to normal mucosa cells, thus establishing an autocrine c-kit-mediated loop. In addition, we noted that exogenous SCF contributes to anchorage-independent growth of HT-29 colon carcinoma cells in semisolid medium. Here, we investigated possible roles of the c-kit/SCF autocrine/paracrine system in survival and invasive capacity of DLD-1 colon carcinoma cells. We report that SCF was required for migration and invasion of DLD-1 cells through reconstituted basement membranes (Matrigel) and up-regulated gelatinase (matrix metalloproteinase-9) activity in DLD-1 cells. Furthermore, we describe that SCF supported survival of DLD-1 cells in growth factor-deprived conditions. These results suggest multiple roles of c-kit activation in support of the malignant phenotype of DLD-1 cells related to growth, survival, migration, and invasive potential.

This article has been cited by other articles:

				A. Zeuner, M. Signore, D. Martinetti, M. Bartucci, C. Peschle, and R. De Maria Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor Cancer Res., May 15, 2007; 67(10): 4767 - 4773. [Abstract] [Full Text] [PDF]

				F. H. Psahoulia, S. Moumtzi, M. L. Roberts, T. Sasazuki, S. Shirasawa, and A. Pintzas Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells Carcinogenesis, May 1, 2007; 28(5): 1021 - 1031. [Abstract] [Full Text] [PDF]

				Y.-W. E. Chang, J. W. Marlin, T. W. Chance, and R. Jakobi RhoA Mediates Cyclooxygenase-2 Signaling to Disrupt the Formation of Adherens Junctions and Increase Cell Motility Cancer Res., December 15, 2006; 66(24): 11700 - 11708. [Abstract] [Full Text] [PDF]

				M. R. Raspollini, G. Amunni, A. Villanucci, P. Pinzani, L. Simi, M. Paglierani, and G. L. Taddei c-Kit Expression in Patients with Uterine Leiomyosarcomas: A Potential Alternative Therapeutic Treatment Clin. Cancer Res., May 15, 2004; 10(10): 3500 - 3503. [Abstract] [Full Text] [PDF]

				R. Yorke, M. Chirala, and M. Younes c-Kit Proto-Oncogene Product Is Rarely Detected in Colorectal Adenocarcinoma J. Clin. Oncol., October 15, 2003; 21(20): 3885 - 3886. [Full Text] [PDF]

				R. Komdeur, H. J. Hoekstra, W. M. Molenaar, E. van den Berg, N. Zwart, E. Pras, I. Plaza-Menacho, R. M. W. Hofstra, and W. T. A. van der Graaf Clinicopathologic Assessment of Postradiation Sarcomas: KIT as a Potential Treatment Target Clin. Cancer Res., August 1, 2003; 9(8): 2926 - 2932. [Abstract] [Full Text] [PDF]

				A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins Blood, July 1, 2003; 102(1): 87 - 93. [Abstract] [Full Text] [PDF]

				Y. R. Choi, H. Kim, H. J. Kang, N.-G. Kim, J. J. Kim, K.-S. Park, Y.-K. Paik, H. O. Kim, and H. Kim Overexpression of High Mobility Group Box 1 in Gastrointestinal Stromal Tumors with KIT Mutation Cancer Res., May 1, 2003; 63(9): 2188 - 2193. [Abstract] [Full Text] [PDF]

				S. Attoub, C. Rivat, S. Rodrigues, S. Van Bocxlaer, M. Bedin, E. Bruyneel, C. Louvet, M. Kornprobst, T. Andre, M. Mareel, et al. The c-kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy Cancer Res., September 1, 2002; 62(17): 4879 - 4883. [Abstract] [Full Text] [PDF]